{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Meric-Bernstam F"],"funding":["Roche (Roche Holding)","Cancer Research UK","NCATS NIH HHS","Genentech","Roche","Medical Research Council","Genentech (Genentech USA)","NCI NIH HHS","Wellcome Trust"],"pagination":["2935-2944"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7618057"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(14)"],"pubmed_abstract":["<h4>Purpose</h4>A combination of two HER2-directed antibodies, pertuzumab and trastuzumab (P + T), has antitumor activity in HER2-positive colorectal cancer. Although liquid biopsies are increasingly being used in clinical oncology, the association between tumor and ctDNA ERBB2 status and ctDNA monitoring for early response and resistance are unknown.<h4>Patients and methods</h4>Eighty-five patients with ERBB2-amplified and/or -overexpressed colorectal cancer were treated with P + T in the MyPathway trial; 42 had ctDNA testing at cycle (C) 1 day (D) 1, and 38 had longitudinal plasma tested for ctDNA. We analyzed the ctDNA versus tissue ERBB2 concordance, genomic co-alterations, and ctDNA dynamics and association with response.<h4>Results</h4>Forty-one (98%) of 42 patients had genomic alter"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial."],"pmcid":["PMC7618057"],"funding_grant_id":["UL1 TR000371","P30 CA016672","CC2041"],"pubmed_authors":["Bose R","Swanton C","Malato J","Meric-Bernstam F","Burris HA","Spigel DR","Price R","Sweeney CJ","Kurzrock R","Raghav KPS","Grindheim JM","Friedman CF","Schulze K","Espenschied CR"],"additional_accession":[]},"is_claimable":false,"name":"ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.","description":"<h4>Purpose</h4>A combination of two HER2-directed antibodies, pertuzumab and trastuzumab (P + T), has antitumor activity in HER2-positive colorectal cancer. Although liquid biopsies are increasingly being used in clinical oncology, the association between tumor and ctDNA ERBB2 status and ctDNA monitoring for early response and resistance are unknown.<h4>Patients and methods</h4>Eighty-five patients with ERBB2-amplified and/or -overexpressed colorectal cancer were treated with P + T in the MyPathway trial; 42 had ctDNA testing at cycle (C) 1 day (D) 1, and 38 had longitudinal plasma tested for ctDNA. We analyzed the ctDNA versus tissue ERBB2 concordance, genomic co-alterations, and ctDNA dynamics and association with response.<h4>Results</h4>Forty-one (98%) of 42 patients had genomic alter","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-04-08T16:11:17.714Z","creation":"2026-04-08T06:05:21.036Z"},"accession":"S-EPMC7618057","cross_references":{"pubmed":["40512191"],"doi":["10.1158/1078-0432.CCR-24-2763"]}}